Mutated G proteins as drug targets.

Area of Science:

• Molecular Biology
• Pharmacology
• Genetics

Background:

• G proteins are key signal transducers downstream of G protein-coupled receptors (GPCRs).
• Traditionally considered 'undruggable', G proteins play vital roles in physiology.
• Mutations in G proteins are increasingly linked to oncogenesis and neurodevelopmental disorders.

Purpose of the Study:

• To review known G protein modulators and pathogenic mutations.
• To discuss emerging therapeutic opportunities for targeting mutant G proteins.
• To highlight the potential for selective intervention in diseases driven by G protein mutations.

Main Methods:

• Literature review of G protein modulators.
• Analysis of reported pathogenic G protein mutations.
• Discussion of therapeutic strategies for mutant G proteins.

Main Results:

• Recent development of small molecules and peptides targeting wild-type (WT) G proteins, though none are in clinical use.
• Identification of numerous somatic and germline G protein mutations implicated in diseases.
• Emerging evidence suggests mutant G proteins as viable therapeutic targets.

Conclusions:

• Targeting mutant G proteins offers a promising strategy for selective therapeutic intervention.
• This approach has the potential to spare normal signaling, reducing side effects.
• Further research into G protein modulators and mutations could lead to novel treatments for cancer and neurodevelopmental disorders.